Abstract
BACKGROUND AND PURPOSE Strategies designed to enhance cerebral cAMP have been proposed as symptomatic treatments to counteract cognitive deficits. However, pharmacological therapies aimed at reducing PDE4, the main class of cAMP catabolizing enzymes in the brain, produce severe emetic side effects. We have recently synthesized a 3-cyclopentyloxy-4-methoxybenzaldehyde derivative, structurally related to rolipram, and endowed with selective PDE4D inhibitory activity. The aim of the present study was to investigate the effect of the new drug, namely GEBR-7b, on memory performance, nausea, hippocampal cAMP and amyloid-beta (A beta) levels.
Original language | English |
---|---|
Pages (from-to) | 2054-2063 |
Journal | British Journal of Pharmacology |
Volume | 164 |
Issue number | 8 |
DOIs | |
Publication status | Published - Dec 2011 |
Keywords
- PDE4 inhibitor
- memory
- phosphodiesterase
- cyclic AMP
- rolipram
- emesis